A Distinctive Metabolomics Pattern Associated with the Administration of Combined Sacubitril/Valsartan to Healthy Subjects: A Kinetic Approach

<b>Background/Objective:</b> Sacubitril/Valsartan are a combination drug approved for heart failure treatment, known to enhance natriuretic peptide activity and inhibit the renin–angiotensin–aldosterone system (RAAS). While its clinical efficacy is well-established, its broader impact on...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Pharmaceuticals
المؤلفون الرئيسيون:	Randh AlAhmari, Hana M. A. Fakhoury, Reem AlMalki, Hatouf H. Sukkarieh, Lina Dahabiyeh, Tawfiq Arafat, Anas M. Abdel Rahman
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2025-08-01
الموضوعات:	Sacubitril/Valsartan metabolomics LC-QToF HRMS pyrimidine metabolism pharmacokinetics uridine triphosphate
الوصول للمادة أونلاين:	https://www.mdpi.com/1424-8247/18/9/1264

مواد مشابهة

Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India
حسب: Uday M. Jadhav, وآخرون
منشور في: (2024-11-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
حسب: David Carballo, وآخرون
منشور في: (2020-06-01)

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
حسب: Hisham A. Badreldin, وآخرون
منشور في: (2022-02-01)

Sacubitril/Valsartan Ameliorates Crizotinib-Induced Cardiotoxicity in Mice
حسب: Lijun Cheng, وآخرون
منشور في: (2023-07-01)

Chronic Diarrhoea associated with Sacubitril-Valsartan use in an Elderly Female - The Benefits of Unprescribing
حسب: Sankha Shubhra Chakrabarti, وآخرون
منشور في: (2020-01-01)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
حسب: Ying‐Hsiang Lee, وآخرون
منشور في: (2021-04-01)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
حسب: Maura Brioschi, وآخرون
منشور في: (2023-03-01)

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
حسب: Paolo Tolomeo, وآخرون
منشور في: (2022-06-01)

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
حسب: Pema Raj, وآخرون
منشور في: (2021-08-01)

Baseline left ventricular ejection fraction predicts the magnitude of improvement in patients taking sacubitril/valsartan
حسب: José-Manuel Rubio-Campal, وآخرون
منشور في: (2025-06-01)

Retrospective analysis of influences of sacubitril/valsartan in patients with diabetes with poorly controlled blood pressure in Japan
حسب: Shun Ito, وآخرون
منشور في: (2025-10-01)

Improvement in quality of life with sacubitril/ /valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry
حسب: José Manuel Rubio Campal, وآخرون
منشور في: (2021-05-01)

Frecuencia y distribución geográfica del uso de sacubitril/valsartán en Colombia entre los años 2019 y 2020
حسب: Nancy Herrera-Leaño, وآخرون
منشور في: (2024-01-01)

The use of sacubitril/valsartan in different forms of heart failure
حسب: Mohammad Abumayyaleh, وآخرون
منشور في: (2025-06-01)

The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure
حسب: Alireza Arzhangzadeh, وآخرون
منشور في: (2025-05-01)

Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients
حسب: Bin Wang, وآخرون
منشور في: (2022-03-01)

Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome
حسب: Shuangcui Wang, وآخرون
منشور في: (2023-05-01)

Effects of sacubitril/valsartan in patients with cancer therapy-related heart failure
حسب: Marina V. Vitsenya, وآخرون
منشور في: (2023-09-01)

Effects and clinical outcomes of early initiation of sacubitril/valsartan in patients with chronic heart failure with a low ejection fraction
حسب: Z. D. Kobalava, وآخرون
منشور في: (2020-12-01)

Case Series: Sacubitril/Valsartan Role for Chemotherapy-Induced Cardiotoxicity: An in-Depth Investigation in Saudi Arabia
حسب: Alshammari A, وآخرون
منشور في: (2024-01-01)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
حسب: Cong Zhao, وآخرون
منشور في: (2022-11-01)

Sacubitril/valsartan in Heart Failure and Beyond—From Molecular Mechanisms to Clinical Relevance
حسب: Maja Nikolic, وآخرون
منشور في: (2022-06-01)

Long-Term Effects of Sacubitril/Valsartan After Chemotherapy for Breast Cancer in Patients With Chronic heart Failure
حسب: S. G. Kanorskiy, وآخرون
منشور في: (2024-03-01)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
حسب: Marcely Gimenes Bonatto, وآخرون
منشور في: (2020-06-01)

Effectiveness of Sacubitril/Valsartan in Preventing Heart Failure in STEMI Post-Percutaneous Coronary Intervention
حسب: Nobian Andre, وآخرون
منشور في: (2023-12-01)

Association between treatment with sacubitril/valsartan and the risk of Alzheimer’s disease: a clinical update
حسب: Antoine Garnier-Crussard
منشور في: (2024-08-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
حسب: Ning Wang, وآخرون
منشور في: (2024-12-01)

Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan
حسب: Reza Mohebi, وآخرون
منشور في: (2023-10-01)

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats
حسب: Einar Sjaastad Nordén, وآخرون
منشور في: (2025-04-01)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
حسب: Ying Ding, وآخرون
منشور في: (2023-12-01)

Repurposing Artrestan (Sacubitril/Valsartan), unveiling its anti-inflammatory and fibrinolytic properties in ulcerative colitis in rats
حسب: Khatereh Kharazmi, وآخرون
منشور في: (2025-10-01)

Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease
حسب: Narainrit Karuna, وآخرون
منشور في: (2025-05-01)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
حسب: Juan Jiang, وآخرون
منشور في: (2023-03-01)

The history and mystery of sacubitril/valsartan: From clinical trial to the real world
حسب: Mingsong Zhang, وآخرون
منشور في: (2023-03-01)

Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study
حسب: Daina Martínez‐Falguera, وآخرون
منشور في: (2025-06-01)

Sacubitril with valsartan, a modern pharmacotherapy in heart failure - a literature review
حسب: Bartosz Sadłowski, وآخرون
منشور في: (2024-07-01)

Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats
حسب: Mohd Imran, وآخرون
منشور في: (2019-01-01)

Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction
حسب: Pei Yang, وآخرون
منشور في: (2023-01-01)

A Simple Score to Identify Super-Responders to Sacubitril/Valsartan in Ambulatory Patients With Heart Failure
حسب: Carles Moliner-Abós, وآخرون
منشور في: (2021-02-01)

First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy
حسب: S. G. Kanorskiy, وآخرون
منشور في: (2019-10-01)